[Skip to Content]
[Skip to Content Landing]
Views 919
Citations 0
Special Communication
January 5, 2017

Diagnosis and Management of Waldenström MacroglobulinemiaMayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

Author Affiliations
  • 1Division of Hematology, Mayo Clinic, Rochester, Minnesota
  • 2Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona
  • 3Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida
  • 4Division of Neurology, Mayo Clinic, Rochester, Minnesota
  • 5Division of Hematopathology, Mayo Clinic, Rochester, Minnesota
  • 6Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota
  • 7Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
  • 8Division of Nephrology, Mayo Clinic, Rochester, Minnesota
JAMA Oncol. Published online January 5, 2017. doi:10.1001/jamaoncol.2016.5763
Abstract

Importance  Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system.

Observations  Waldenström macroglobulinemia remains a rare, incurable cancer, with a heterogeneous disease course. The major classes of effective agents in WM include monoclonal antibodies, alkylating agents, purine analogs, proteasome inhibitors, immunomodulatory drugs, and mammalian target of rapamycin inhibitors. However, the highest-quality evidence from rigorously conducted randomized clinical trials remains scant.

Conclusions and Relevance  Recognizing the paucity of data, we advocate participation in clinical trials, if available, at every stage of WM. Specific indications exist for initiation of therapy. Outside clinical trials, based on the synthesis of available evidence, we recommend bendamustine-rituximab as primary therapy for bulky disease, profound hematologic compromise, or constitutional symptoms attributable to WM. Dexamethasone-rituximab-cyclophosphamide is an alternative, particularly for nonbulky WM. Routine rituximab maintenance should be avoided. Plasma exchange should be promptly initiated before cytoreduction for hyperviscosity-related symptoms. Stem cell harvest for future use may be considered in first remission for patients 70 years or younger who are potential candidates for autologous stem cell transplantation. At relapse, retreatment with the original therapy is reasonable in patients with prior durable responses (time to next therapy ≥3 years) and good tolerability to previous regimen. Ibrutinib is efficacious in patients with relapsed or refractory disease harboring MYD88 L265P mutation. In the absence of neuropathy, a bortezomib-rituximab–based option is reasonable for relapsed or refractory disease. In select patients with chemosensitive disease, autologous stem cell transplantation should be considered at first or second relapse. Everolimus and purine analogs are suitable options for refractory or multiply relapsed WM. Our recommendations are periodically updated as new, clinically relevant information emerges.

×